Table of Contents
This report elaborates on the present landscape for major segments of the GPCR drug market, discusses and relates the future trends and strategies to the breakthrough developments within the market. The estimations for the period between 2013 and 2018 are applied on the sales figures for the global and regional market forecasting.
Use this report to:
- Gain in detail information about the GPCR market by disease type as well as by drug group.
- Analyze prospects in the pipeline for GPCR targeting drugs.
- Learn about the key drivers and limiting factors as well as major threats versus opportunities for the future growth and direction of the GPCR market.
- The global G protein, coupled receptors (GPCR) targeting drug market sharply fell in the last three years due to a series of patent expirations of blockbuster products. The market receded from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate (CAGR) between 2010 and 2013. With the introduction of novel pharmacecuticals and newly appearing classes of drugs, BCC Research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013 to 2018.
- The US market was $48.1 billion in 2012. This market is predicted to decrease to $44.5 billion by 2013. With a CAGR of 2.0% from 2013 to 2018, it is expected that the market would recover and reach $49.1 billion by 2018.
- The BRIC market achieved a positive CAGR during the previous three years and increased its market share to nearly $8 billion by 2013. With a CAGR of 5.4% from 2013 to 2018, BCC Research estimates this market to reach $10.3 billion by 2018.
Introduction & Scope
The aim of this work is to study the global market for G Protein Coupled Receptor, or GPCR-targeting drugs, and to provide beneficial information on the current and future
participators that determine the market’s short-term directions.
This report elaborates on the present landscape for major segments of the GPCR drug market, which includes three extensive sets of drug groups under Class A, B and C
GPCR-targeting drugs; and furthermore, the report discusses and relates the future trends and strategies to the breakthrough developments within the market. The key drivers and limiting factors as well as major threats versus opportunities for the future growth and direction of the market were identified and addressed within this
report. The classification and comparison of the distinct segments of the GPCR drugs were performed and conveyed via the report, along with the anticipated extensions to
The industry dynamics and characteristics were analyzed and utilized for the interpretation and forecasting for the overall GPCR drugs. The obtained revenues for the majority of the indicated products constituting the market were collected and broken down by region. The estimations for the period between 2013 and 2018 were applied on the sales figures for the global and regional market forecasting. The report also sheds light on the therapeutic applications of the marketed GPCR drugs; the breakdown by therapeutic applications was accomplished under eight main groups and multiple subgroups. The regulatory views on the marketed and in-development products were also mentioned through the recent approvals and enforced safety measures for the product manufacturers.
REASONS FOR DOING THE STUDY
The recent technological advances and accumulating structural and functional literature on the physiological and pharmacological features of the GPCRs have shown that these targets have versatile utilities in the treatment of a broad spectrum of diseases across almost every therapeutic area. The multitude of the untapped orphan GPCR targets and the previously undruggable targets that are becoming viable just recently attracted companies from various backgrounds of specialties and expertise to invest more in the research and development of the GPCR drugs.
Innovation and improvement are the offsetting factors for the effects of the ongoing patent expirations and concentrated regression of market sub-segments following peak
years of sales. The innovations under existing and newly appearing market segments were provided in the report; trends for improvement and seizable market opportunities
were mentioned under therapeutic applications.
This study adds value to the processes of the discovery, development and commercialization of the GPCR-targeting drugs. Pharmaceutical and biotechnology companies, research institutes and healthcare professionals, large companies and small to medium-size enterprises will find this report to be of great utility.
SCOPE OF THE STUDY
The scope of this study encompasses the GPCR targeting drugs in pharmaceutical and biopharmaceutical markets. BCC Research analyzed each market and its applications,
regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The strong growing market for the GPCR drugs includes the countries of the EU such as the U.K., France, Germany, Spain and Italy, and also include the emerging countries such as China, Brazil, South Korea, Taiwan, Mexico and other countries.
METHODOLOGY AND INFORMATION SOURCES
Both primary and secondary research were conducted and used in preparing this study. The analyst of the report conducted a comprehensive literature search from public,
private and government sources, which included company publications, industrial and market reports available in physical or electronic format, research papers, scientific
journals and various other professionally written dedicated sources; as well as industrial databases, company and product literature.
Data were obtained through interviews and correspondence with the research-based companies and technical experts of the GPCR-based drug lead discovery. Projections were based on estimates such as the current number of end users, potential end users, market entry products, patent expirations, regional dynamics, disease prevalence and other market trends.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
This new 75-country survey from VPGMarketResearch.com provides granular data and analysis not available from any other published source. The survey is designed to help current suppliers and potential market ...
This new report from VPGMarketResearch.com provides granular analysis of the Europe diagnostic testing market, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, ...
This new report from VPGMarketResearch.com provides granular analysis of the Asia-Pacific diagnostic testing market, including Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, ...